TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01082874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Clonidine
Description: Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Clonidine
Description: Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Clonidine
Description: Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Clonidine
Description: Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active ASA
Description: Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active ASA
Description: Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ASA
Description: Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ASA
Description: Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
Study: NCT02084706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (20 g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (20 g)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: J-tip lidocaine administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triamcinolone (20 g) Injection over the A1 pulley.
Study: NCT04270942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teplizumab
Description: anti-CD3 humanized monoclonal antibody
Study: NCT03374683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RR Digital Tool
Description: Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RR In-Person Workshop
Description: Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Position Statement on Active Outdoor Play
Description: The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015).
Study: NCT03469986

Intervention type: DEVICE
Intervention: Marcus Autism Center Investigational Device
Description: This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.

Intervention type: DEVICE
Intervention: Marcus Autism Center Investigational Device
Description: This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
Study: NCT04265729

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Neocate Infant and Junior marketed products
Description: use of Neocate Infant and Junior marketed products
Study: NCT03582553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Naringenin
Description: An extract of Citrus Sinensis containing naringenin and its precursor naringin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Naringenin
Description: An extract of Citrus Sinensis containing naringenin and its precursor naringin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Naringenin
Description: An extract of Citrus Sinensis containing naringenin and its precursor naringin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Naringenin
Description: An extract of Citrus Sinensis containing naringenin and its precursor naringin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose
Study: NCT01562314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003
Description: 1 to 5 50 mg capsules taken BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 5 matching capsules taken BID
Study: NCT01539733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
Study: NCT03897153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONAS® Ultrasound Device
Description: The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
Study: NCT01190761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine 4 mg Tablet, single dose
Description: A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reminyl 4 mg Tablet, single dose
Description: B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
Study: NCT02099877

Intervention type: DRUG
Intervention: Fentanyl
Description: Epidural analgesia will be initiated with 100µg of epidural fentanyl
Study: NCT03023774

Intervention type: DRUG
Group type: OTHER
Intervention: Neupogen
Description: neupogen 30 IU once intrauterine at the time of ovum pickup
Study: NCT04277637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given as an intravenous infusion administered per label.
Study: NCT03031483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin and lenalidomide
Description: Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total.
Study: NCT03393884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMNN-001
Description: IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 IV over 1 hour on Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6 IV over 1 hour on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 IV over 3 hours on Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 IV over 3 hours on Day 1 of each cycle
Study: NCT01190475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active treatment with a high dose of BGS649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active treatment with a low dose of BGS649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment to blind study
Study: NCT01503151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Description: Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (IBM)
Description: Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention and Interpretive biases modification (CBM)
Description: Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
Study: NCT01971411

Intervention type: DRUG
Intervention: Calcium 500mg with 200 IU Vitamin D - 2 tablets daily

Intervention type: PROCEDURE
Intervention: Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH

Intervention type: BEHAVIORAL
Intervention: Usual sun exposure documentation

Intervention type: BEHAVIORAL
Intervention: Dietary intake of calcium, vitamin D, magnesium
Study: NCT01348945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional ACL rehabilitation program
Description: Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
Study: NCT00976911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan
Description: 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
Study: NCT04608110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX030
Description: In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
Study: NCT02836210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 27-gauge vitrectomy wound construction
Description: Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
Study: NCT01915212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV529
Description: The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9%
Study: NCT01348945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional ACL rehabilitation program
Description: Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
Study: NCT00934973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebeverine
Description: overencapsulated mebeverine 135 mg tds for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebeverine
Description: overencapsulated mebeverine 135 mg tds for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebeverine
Description: overencapsulated mebeverine 135 mg tds for 6 weeks
Study: NCT00624585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~  1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~  1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~  1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily
Study: NCT00742287

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
Description: 200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03834610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine 5 gm oral caps
Description: oral L-arginine 5 gm daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine 5 gm oral caps
Description: oral L-arginine 5 gm daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 10 MG
Description: oral daily tadalafil 10mg for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 10 MG
Description: oral daily tadalafil 10mg for 8 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum testosterone level
Description: measurement of serum testosterone level

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum testosterone level
Description: measurement of serum testosterone level

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum testosterone level
Description: measurement of serum testosterone level

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: serum testosterone level
Description: measurement of serum testosterone level

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1C
Description: measurement of HbA1C levels

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1C
Description: measurement of HbA1C levels

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1C
Description: measurement of HbA1C levels

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: HbA1C
Description: measurement of HbA1C levels

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: penile doppler
Description: penile doppler to measure the degree of erection and penile vasculature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: penile doppler
Description: penile doppler to measure the degree of erection and penile vasculature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: penile doppler
Description: penile doppler to measure the degree of erection and penile vasculature

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: penile doppler
Description: penile doppler to measure the degree of erection and penile vasculature
Study: NCT03389724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capoten®
Description: ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
Study: NCT03911752

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews were used to obtain the main data in this study.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews were used to obtain the main data in this study.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews were used to obtain the main data in this study.

Intervention type: OTHER
Intervention: Canadian Occupational Performance Measure
Description: The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
Study: NCT00934973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcellulose
Description: overencapsulated methylcellulose 3 tablets bd for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcellulose
Description: overencapsulated methylcellulose 3 tablets bd for 6 weeks
Study: NCT00052299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Study: NCT00934973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcellulose
Description: overencapsulated methylcellulose 3 tablets bd for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: overencapsulated placebo tablets 1 tds for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: overencapsulated placebo tablets 1 tds for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: overencapsulated placebo tablets 1 tds for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT website with support
Description: cognitive behavioral therapy with nurse telephone session and email support
Study: NCT00052299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Study: NCT00934973

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT website with support
Description: cognitive behavioral therapy with nurse telephone session and email support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT website with support
Description: cognitive behavioral therapy with nurse telephone session and email support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No website
Description: No CBT website

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No website
Description: No CBT website

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No website
Description: No CBT website

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT website with minimal support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT website with minimal support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT website with minimal support
Study: NCT02709785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmartMouth Clinical DDS mouthrinse
Description: Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
Study: NCT01803191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin 3 g
Description: Unique oral dosis of fosfomycin 1 hour before biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 500 mg
Description: Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
Study: NCT04556955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston technique
Description: Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: post isometric relaxation
Description: Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier